Compare NBIX & NTNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | NTNX |
|---|---|---|
| Founded | 1992 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5B | 18.3B |
| IPO Year | 1996 | 2015 |
| Metric | NBIX | NTNX |
|---|---|---|
| Price | $157.22 | $67.69 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 22 | 19 |
| Target Price | ★ $180.91 | $62.29 |
| AVG Volume (30 Days) | 949.8K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.95 | ★ 227.45 |
| EPS | ★ 3.30 | 0.82 |
| Revenue | $161,626,000.00 | ★ $2,537,927,000.00 |
| Revenue This Year | $24.73 | $13.44 |
| Revenue Next Year | $13.14 | $13.03 |
| P/E Ratio | ★ $47.34 | $80.39 |
| Revenue Growth | ★ 977.51 | 18.11 |
| 52 Week Low | $122.14 | $34.01 |
| 52 Week High | $186.12 | $79.76 |
| Indicator | NBIX | NTNX |
|---|---|---|
| Relative Strength Index (RSI) | 52.22 | 55.60 |
| Support Level | $152.67 | $44.85 |
| Resistance Level | $161.00 | $68.80 |
| Average True Range (ATR) | 4.14 | 2.11 |
| MACD | 0.85 | -0.62 |
| Stochastic Oscillator | 84.92 | 18.92 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.